-
EP3352858
European procedure
- EP About this file
- EP Legal status
- EP Federated register
- EP Event history
- EP Citations
- EP Patent family
- EP All documents
Extract from the Register of European Patents
EP About this file: EP3352858
| EP3352858 - ANTIBODY THAT BINDS TO HUMAN PROGRAMMED DEATH LIGAND 2 (PD-L2) AND USES THEREOF [Right-click to bookmark this link] | Status | Examination is in progress Status updated on 02.09.2022 Database last updated on 03.06.2024 | |
| Former | Request for examination was made Status updated on 29.06.2018 | ||
| Former | The international publication has been made Status updated on 01.04.2017 | Most recent event Tooltip | 12.09.2023 | New entry: Renewal fee paid | Applicant(s) | For all designated states Merck Sharp & Dohme LLC 126 East Lincoln Avenue Rahway, New Jersey 07065 / US | [2022/42] |
| Former [2018/31] | For all designated states Merck Sharp & Dohme Corp. 126 East Lincoln Avenue Rahway, NJ 07065-0907 / US | Inventor(s) | 01 /
YEARLEY, Jennifer, H. 901 South California Avenue Palo Alto, California 94304 / US | 02 /
LIANG, Linda 128 Ada Avenue Apt. 8 Mountain View, California 94043 / US | 03 /
BIGLER, Michael Eric 901 South California Avenue Palo Alto, California 94304 / US | 04 /
GIBSON, Christopher John 707 Haldane Drive Kennett Square, Pennsylvania 19348 / US | [2018/31] | Representative(s) | Merck Sharp & Dohme LLC 120 Moorgate London EC2M 6UR / GB | [N/P] |
| Former [2018/31] | Böhles, Elena Merck Sharp & Dohme Limited Hertford Road Hoddesdon, Herts EN11 9BU / GB | Application number, filing date | 16849405.2 | 20.09.2016 | [2018/31] | WO2016US52569 | Priority number, date | US201562221472P | 21.09.2015 Original published format: US 201562221472 P | [2018/31] | Filing language | EN | Procedural language | EN | Publication | Type: | A1 Application with search report | No.: | WO2017053250 | Date: | 30.03.2017 | Language: | EN | [2017/13] | Type: | A1 Application with search report | No.: | EP3352858 | Date: | 01.08.2018 | Language: | EN | The application published by WIPO in one of the EPO official languages on 30.03.2017 takes the place of the publication of the European patent application. | [2018/31] | Search report(s) | International search report - published on: | US | 30.03.2017 | (Supplementary) European search report - dispatched on: | EP | 20.03.2019 | Classification | IPC: | A61P35/00, C07K16/28, C07K16/46, C12N15/13, G01N33/574 | [2019/14] | CPC: |
C07K16/2827 (EP,US);
A61K39/395 (US);
A61P35/00 (EP,US);
G01N33/57492 (US);
C07K2317/20 (US);
C07K2317/52 (US);
C07K2317/56 (US);
C07K2317/565 (US);
C07K2317/567 (US);
|
| Former IPC [2018/31] | A61P35/00, C07K16/28, C07K16/46, C12N15/13 | Designated contracting states | AL, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LI, LT, LU, LV, MC, MK, MT, NL, NO, PL, PT, RO, RS, SE, SI, SK, SM, TR [2018/31] | Title | German: | AN DEN MENSCHLICHEN PROGRAMMIERTEN TODESLIGANDEN 2 (PD-L2) BINDENDER ANTIKÖRPER UND DESSEN VERWENDUNG | [2018/31] | English: | ANTIBODY THAT BINDS TO HUMAN PROGRAMMED DEATH LIGAND 2 (PD-L2) AND USES THEREOF | [2018/31] | French: | ANTICORPS QUI SE LIE À LA FORME HUMAINE DU LIGAND-2 DE LA PROTÉINE 1 DE MORT CELLULAIRE PROGRAMMÉE (PD-L2), ET UTILISATION DE CE DERNIER | [2018/31] | Entry into regional phase | 23.04.2018 | National basic fee paid | 23.04.2018 | Search fee paid | 23.04.2018 | Designation fee(s) paid | 23.04.2018 | Examination fee paid | Examination procedure | 19.04.2018 | Date on which the examining division has become responsible | 23.04.2018 | Examination requested [2018/31] | 29.11.2019 | Despatch of communication that the application is deemed to be withdrawn, reason: reply to the communication from the examining division not received in time | 22.01.2020 | Amendment by applicant (claims and/or description) | 01.09.2022 | Despatch of a communication from the examining division (Time limit: M06) | 06.03.2023 | Reply to a communication from the examining division | Request for further processing for: | The application is deemed to be withdrawn due to failure to indicate the wish to proceed further with the application | 22.01.2020 | Request for further processing filed | 22.01.2020 | Full payment received (date of receipt of payment) Request granted | 12.02.2020 | Decision despatched | The application is deemed to be withdrawn due to failure to reply to the Extended European Search Report/Written Opinion of the International Searching Authority/International Preliminary Examination Report/Supplementary international search report/Supplementary European search report | 22.01.2020 | Request for further processing filed | 22.01.2020 | Full payment received (date of receipt of payment) Request granted | 12.02.2020 | Decision despatched | Fees paid | Renewal fee | 11.09.2018 | Renewal fee patent year 03 | 11.09.2019 | Renewal fee patent year 04 | 11.09.2020 | Renewal fee patent year 05 | 09.09.2021 | Renewal fee patent year 06 | 09.09.2022 | Renewal fee patent year 07 | 12.09.2023 | Renewal fee patent year 08 |
| Opt-out from the exclusive Tooltip competence of the Unified Patent Court | See the Register of the Unified Patent Court for opt-out data | ||
| Responsibility for the accuracy, completeness or quality of the data displayed under the link provided lies entirely with the Unified Patent Court. | Documents cited: | Search | [A]WO2010036959 (DANA FARBER CANCER INST INC [US], et al) [A] 1-20 * example -; claim - *; | [XYI]WO2014151006 (GENENTECH INC [US], et al) [X] 18 * claim - * [Y] 20 [I] 19; | [XYI]US9073994 (HONJO TASUKU [JP], et al) [X] 18 * claim - * [Y] 20 [I] 19; | [XPAI]WO2016144673 (DANA FARBER CANCER INST INC [US]) [XP] 18,19 * page 2, line 23 - page 3, line 2; example -; claim - * * page 121, line 15 - line 23 * [A] 2,4,13,17[I] 1,3,5-12,14-16,20; | [IAY] - J. M. TAUBE ET AL, "Association of PD-1, PD-1 Ligands, and Other Features of the Tumor Immune Microenvironment with Response to Anti-PD-1 Therapy", CLINICAL CANCER RESEARCH, US, (20140408), vol. 20, no. 19, doi:10.1158/1078-0432.CCR-13-3271, ISSN 1078-0432, pages 5064 - 5074, XP055291958 [I] 1,3,5-12,14-16 * page 5065, column r, paragraph l * [A] 2,4,13,17-19 [Y] 20 DOI: http://dx.doi.org/10.1158/1078-0432.CCR-13-3271 | [IAY] - SHI MIN ET AL, "Expression of programmed cell death 1 ligand 2 (PD-L2) is a distinguishing feature of primary mediastinal (thymic) large B-cell lymphoma and associated with PDCD1LG2 copy gain.", THE AMERICAN JOURNAL OF SURGICAL PATHOLOGY, (201412), vol. 38, no. 12, ISSN 1532-0979, pages 1715 - 1723, XP002789151 [I] 1,3,5-12,14-16 * page 1716, column l, paragraph 1 * * page 1716, column r, paragraph 2 * [A] 2,4,13,17-19 [Y] 20 DOI: http://dx.doi.org/10.1097/PAS.0b013e31823651cb | [A] - ANNE M. SCHULTHEIS ET AL, "PD-L1 expression in small cell neuroendocrine carcinomas", EUROPEAN JOURNAL OF CANCER, AMSTERDAM, NL, (20150201), vol. 51, no. 3, doi:10.1016/j.ejca.2014.12.006, ISSN 0959-8049, pages 421 - 426, XP055431576 [A] 1-20 * abstract * DOI: http://dx.doi.org/10.1016/j.ejca.2014.12.006 | International search | [A]US2008118511 (FREEMAN GORDON [US], et al) [A] 1-5, 7-10, 18, 19 * entire document entire document *; | [A]US2014234296 (SHARMA MANOJ K [US], et al) [A] 1-5, 7-10, 18, 19* entire document *; | [A]WO2015088847 (GLAXOSMITHKLINE LLC [US], et al) [A] 1-5, 7-10, 18, 19 * entire document *; | [A]US2015197571 (FREEMAN GORDON J [US], et al) [A] 1-5, 7-10, 18, 19 * ) entire document *; | [X]WO2015119923 (PFIZER [US], et al) [X] 18, 19 * entire document * |